Datopotamab Deruxtecan: First Approval

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Datopotamab deruxtecan (DATROWAY®) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2 (TROP2).
• It is developed by Daiichi Sankyo and AstraZeneca for treating solid tumors.
• This conjugate represents a novel therapeutic approach in oncology.

Purpose of the Study:

• To summarize the development milestones of datopotamab deruxtecan.
• To highlight its recent approvals for specific breast cancer indications.
• To provide an overview of its regulatory journey.

Main Methods:

• Review of regulatory filings and clinical development data.
• Analysis of approval dates and geographical regions.
• Summary of patient populations and prior treatment criteria.

Main Results:

• Datopotamab deruxtecan received approval in Japan (December 27, 2024) for HR+, HER2- unresectable or recurrent breast cancer post-chemotherapy.
• US approval (January 17, 2025) was granted for unresectable or metastatic HR+, HER2- breast cancer with prior endocrine-based therapy and chemotherapy.
• EU approval was obtained for unresectable or metastatic HR+, HER2- breast cancer following endocrine therapy and at least one line of chemotherapy.

Conclusions:

• Datopotamab deruxtecan has achieved significant regulatory milestones with its initial approvals.
• These approvals target a specific, unmet need in HR+, HER2- advanced breast cancer.
• Further regulatory reviews are ongoing in Canada and China.